Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | PRKCH | P24723 | 5/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015247 | 0.86 | KDM4C (0.47) | ADRA2BCTSDLOXL2KDM4CPRKCH | |
| SCHEMBL18290331 | 0.77 | ADRA2B (0.40) | ADRA2BCTSDLOXL2PRKCHPRKCE | |
| Pyridine SCHEMBL7617224 | 0.77 | HRH1 (0.46) | KDM4CLATS1LATS2HRH1 | |
| SCHEMBL1282816 | 0.76 | CTSD (0.46) | ADRA2BCTSDRAD52FDPSF2 | |
| SCHEMBL3223115 | 0.76 | CTSD (0.46) | ADRA2BCTSDRAD52FDPSF2 | |
| SCHEMBL14985489 | 0.76 | CTSD (0.46) | ADRA2BCTSDRAD52FDPSF2 | |
| SCHEMBL714498 | 0.76 | CTSD (0.46) | ADRA2BCTSDPRKCHPRKCEPRKCD | |
| SCHEMBL16596248 | 0.76 | CTSD (0.46) | ADRA2BCTSDROCK2RAD52FDPS | |
| SCHEMBL5495415 | 0.76 | CTSD (0.46) | ADRA2BCTSDROCK2RAD52FDPS | |
| SCHEMBL7054279 | 0.76 | LIMK1 (0.51) | ADRA2BCTSDKDM4CLATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250354196-A1 | BORANES ON SOLID SUPPORTS | ILLUMINA, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4634403-A1 | BORANES ON SOLID SUPPORTS | Illumina, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024130031-A1 | BORANES ON SOLID SUPPORTS | ILLUMINA, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-07-13 | — | — | US | disclosed |
| EP-3151833-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| CN-101072758-B | Quinazoline derivatives | ASTRAZENECA AB | 2013-07-31 | — | — | CN | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0268229-B1 | IMIDAZOLIDINONE COMPOUNDS, PROCESSES FOR PREPARATION THEREOF, COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICAMENTS HAVING THERAPEUTIC VALUE | TANABE SEIYAKU CO., LTD. (JP) | 1992-07-08 | — | — | EP | disclosed |
| CN-1017245-B | Process for preparing imidazolidinone compound | TANABE SEIYAKU CO (JP) | 1992-07-01 | — | — | CN | disclosed |
| US-4886817-A | Imidazolidinones as brain activators | TANABE SEIYAKU CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| CN-87107864-A | Imidazolidinone compound and preparation method thereof | — | 1988-08-31 | — | — | CN | disclosed |
| EP-0268229-A2 | Imidazolidinone compounds, processes for preparation thereof, compositions comprising such compounds, and the use of such compounds for the manufacture of medicaments having therapeutic value | TANABE SEIYAKU CO., LTD. (JP) | 1988-05-25 | — | — | EP | disclosed |
| US-4217350-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-08-12 | — | — | US | disclosed |
| US-4144344-A | ANTITACHYCARDIAC AGENTS AND A-RECEPTOR BLOCKERS | CIBA-GEIGY CORPORATION (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | ADRA2B 4460/4885CTSD 4490/4885LOXL2 4299/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ADRA2B 951/4885CTSD 3886/4885LOXL2 2802/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | ADRA2B 4460/4885CTSD 4490/4885LOXL2 4299/4885 |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | ADRA2B 4460/4885CTSD 4490/4885LOXL2 4299/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | ADRA2B 4460/4885CTSD 4490/4885LOXL2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.